Lee-Ann Watanabe
Zinzino Independent Partner
¡Bienvenido! Soy su consultor independiente, aquí para guiarlo en su viaje de salud.
Press releases - miércoles, 9 de octubre de 2019 13:00 CET
ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2019
Strong sales growth during September; Zinzino based revenue increased 41% and the total group revenue with a total of 30% compared with the previous year. Zinzino based revenue for the third quarter 2019 increased with 41% and the total revenue with 35% compared with previous year.
The revenue in September for Zinzino's sales markets increased by 41% to MSEK 58.3 (41.4) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 36% and amounted to MSEK 4.1 (6.5) due to high level of internal production during the month. Overall the Group increased revenues by 30% to MSEK 62.4 (47.9) compared with the previous year.
The third quarter of 2019 became the strongest quarter in Zinzino based sales so far in the company’s history; the revenue in July - September increased 41% to MSEK 173.2 (123.0) compared with previous year. Total revenue increased by 35% to MSEK 184.9 (136.7)
Accumulated revenue for January – September 2019 increased by 26% MSEK 532.7 (421.5).
Revenues distributed as follows:
| Regions, MSEK |
19-sep | 18-sep | Change | Q3 2019 |
Q3 2018 |
Change | YTD 2019 | YTD 2018 | Change |
| Baltic Markets | 4.1 | 3.6 | 15% | 12.4 | 10.2 | 22% | 38.4 | 31.7 | 21% |
| Nordic Markets | 27.8 | 28.1 | -1% | 86.9 | 85.6 | 2% | 272.6 | 271.1 | 1% |
| Europe Other Markets | 23.1 | 7.9 | 194% | 65.3 | 21.7 | 201% | 164.4 | 55.6 | 195% |
| North America | 1.7 | 1.9 | -12% | 5.4 | 5.5 | -1% | 16.8 | 15.4 | 9% |
| Australia | 1.7 | 0.0 | 3.2 | 0.0 | 4.7 | 0.0 | |||
| Zinzino | 58.3 | 41.4 | 41% | 173.2 | 123.0 | 41% | 496.8 | 373.8 | 33% |
| Faun Pharma | 4.1 | 6.5 | -36% | 11.7 | 13.8 | -15% | 35.9 | 47.7 | -25% |
| Zinzino Group | 62.4 | 47.9 | 30% | 184.9 | 136.7 | 35% | 532.7 | 421.5 | 26% |
The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
email: certifiedadviser@penser.se
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 13:00 the 9th of October 2019.
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.
Compartir esta página
O copiar el link